



Press Release

Monday, April 13, 2009

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE : 532531

NSE : STAR

Strides Arcolab to align its Global Operations into 3 Separate entities Specialty Pharmaceuticals, Pharmaceuticals & R&D

Strides Arcolab Limited (Strides) today announced a major corporate reorganization of its business involving splitting of its operations into 3 separate entities.

- Specialty Pharmaceuticals
- Pharmaceuticals.
- R & D

The process to involve

- Hive-off of Specialty Pharmaceuticals business into a wholly owned subsidiary “Strides Specialties Private Limited”
- Pharmaceuticals Business to continue under “Strides Arcolab Limited”
- Hive-off of R&D business into a wholly owned subsidiary “Strides Technology and Research Private Limited”
- Consolidation of Multiple entities through Merger with the Parent Company

The proposal is subject to requisite corporate, statutory and regulatory approvals, as may be required.

Detailed presentation on the re-organisation forms part of this Press Release.

In a statement issued on this occasion Arun Kumar, Group CEO said, “The reorganisation of business is a major step to attain greater efficiency and accountable customer focussed business units, while still retaining the aggressive and entrepreneurial spirit of Strides. Both our business units will be backed by a strong and independent R&D function”.

He further stated, “The new reorganisation design will ensure an aggressive growth, anchored by specific business strategies and led by an experienced pool of human capital.

Strides Overview

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms, including sterile injectables with dedicated facilities for Penicillin and Penems, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and softgel capsules. Strides operate in and has significant presence in Australia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US-PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides also has a collaboration agreement with Aspen Pharmacare involving a range of products and territories including a Joint Venture in the Oncolytics space in Bangalore. Recently, the JV concluded a significant transaction with GSK to outlicence products for GSK’s emerging market strategies in over 95 countries

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies, Strides employs approximately 2500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information about Strides is available at the company’s website www.stridesarco.com

For further information, please contact:	
Mr. Arun Kumar, Group CEO Tel: +91 80 6658 0110 / 118	Mahesh Nair Corporate Voice Weber Shandwick Mob: +91 98803 76648 Email: maheshn@corvoshandwick.co.in
Mr. T S Rangan, Group CFO Tel: + 91 80 6658 0115	Kasturi Wasmatar Voice Weber Shandwick Mob: +91 99167 28393 Email: kasturi@corvoshandwick.co.in